3 articles
Regeneron exceeded Q2 revenue and profit estimates, driven by a 38% increase in Dupixent sales and strong high-dose Eylea performance. Shares rose nearly 5% after reporting $4.29 billion in quarterly
Regeneron shares fell 11.8% after its experimental fianlimab-cemiplimab combination failed to meet statistical significance in a late-stage melanoma trial against Merck's Keytruda. Despite a numeric i
Stolt-Nielsen withdrew its annual earnings guidance citing unpredictable impacts from the Persian Gulf conflict on chemical shipping and fuel prices. Strait of Hormuz transits remain low, creating unc
ChemBrief